Indian Journal of Sleep Medicine

Register      Login

VOLUME 10 , ISSUE 4 ( October-December, 2015 ) > List of Articles

REVIEW ARTICLE

Pharmacotherapy in Insomnia

Kamlesh Chakravarty, Manjari Tripathi

Citation Information : Chakravarty K, Tripathi M. Pharmacotherapy in Insomnia. Indian Sleep Med 2015; 10 (4):131-139.

DOI: 10.5958/0974-0155.2015.00018.2

License: CC BY-SA 4.0

Published Online: 01-10-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Insomnia is one of the most prevalent sleep disorders. Patients with insomnia tend to have altered quality of life, impaired daytime functioning and increased risk of road traffic accidents. Insomnia is commonly associated with chronic medical conditions and psychiatric illness like depression and anxiety. However, it is now being recognized as an independent disorder. All patients of Insomnia should receive therapy for any medical illness, psychiatric disorders, substance abuse or sleep disorders that might precipitate insomnia. In this review, we discuss the current pharmacotherapeutic options for treatment of insomnia. Research for newer therapeutics for insomnia is often complicated by multifactorial etiology. of insomnia. Understanding the molecular and receptor mechanisms involved in promoting sleep may provide further approaches tothe development of newer drugs.


PDF Share
  1. American Academy of Sleep Medicine. The International Classification of Sleep Disorder. Third Edition. Darien IL, American Academy of Sleep Medicine;2014.
  2. Suri JC, Sen MK, Adhikari T.Epidemiology of Sleep Disorders in the Adult population of Delhi: A Questionnaire-Based Study. Indian J Sleep Medicine 2008;3.4,128-137.
  3. Panda S, Taly AB, Sinha S, Gururaj G, Girish N, Nagaraja D. Sleep-related disorders among a healthy population in South India. Neurol India. 2012;60(1):68-74.
  4. Montgomery P, Dennis J. A systematic review of nonpharmacological therapies for sleep problems in later life. Sleep Med Rev. 2004;8(1):47-62.
  5. Drugs for insomnia. Treat Guidel Med Lett. 2009;7(79):23- 26.
  6. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350.
  7. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ Can Med Assoc J JAssocMedicale Can. 2000;162(2):225-233.
  8. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170-2177.
  9. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009;13(4):265-274.
  10. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry. 1991;52 Suppl:38-41.
  11. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry. 1992;53 Suppl:4-7; discussion 8-9.
  12. Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J ClinPsychopharmacol. 2002;22(3):285-293.
  13. Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53(6):955-962.
  14. Kelly KD, Pickett W, Yiannakoulias N, et al. Medication use and falls in community-dwelling older persons. Age Ageing. 2003;32(5):503-509.
  15. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262(23):3303-3307.
  16. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192-199.
  17. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79-90.
  18. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebocontrolled trial. Sleep. 2008;31(10):1371-1378.
  19. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799.
  20. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep. 1998;21(1):52-68.
  21. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598-603.
  22. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9(1):41-50.
  23. Rondanelli M, Opizzi A, Monteferrario F, Antoniello N, Manni R, Klersy C. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc. 2011;59(1):82-90.
  24. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15(4):385-392.
  25. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. CurrOpinInvestig Drugs LondEngl 2000. 2009;10(7):691- 701.
  26. Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, doublemasked, placebo-controlled phase 3 trials. Lancet Lond Engl. 2015;386(10005):1754-1764..
  27. Quera Salva M-A, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an openlabel study. Int J NeuropsychopharmacolOffSci J CollInt Neuropsychopharmacol CINP. 2007;10(5):691-696.
  28. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461-471.
  29. Hohagen F, Montero RF, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry ClinNeurosci. 1994;244(2):65-72.
  30. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010;33(11):1553- 1561.
  31. Winokur A, DeMartinis NA, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-1229.
  32. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46(4):197-201.
  33. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio MR. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry. 1999;46(1):141-143.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.